Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 30

1.

Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway.

Tong Y, Giaime E, Yamaguchi H, Ichimura T, Liu Y, Si H, Cai H, Bonventre JV, Shen J.

Mol Neurodegener. 2012 Jan 9;7:2. doi: 10.1186/1750-1326-7-2.

PMID:
22230652
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Genetic analysis of Parkinson's disease-linked leucine-rich repeat kinase 2.

Tong Y, Shen J.

Biochem Soc Trans. 2012 Oct;40(5):1042-6. Review.

PMID:
22988862
[PubMed - indexed for MEDLINE]
3.

α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease.

Covy JP, Giasson BI.

Neurotoxicology. 2011 Oct;32(5):622-9. doi: 10.1016/j.neuro.2011.01.003. Epub 2011 Jan 14. Review.

PMID:
21238487
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

A link between LRRK2, autophagy and NAADP-mediated endolysosomal calcium signalling.

Gómez-Suaga P, Churchill GC, Patel S, Hilfiker S.

Biochem Soc Trans. 2012 Oct;40(5):1140-6. Review.

PMID:
22988879
[PubMed - indexed for MEDLINE]
5.

The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.

Cookson MR.

Nat Rev Neurosci. 2010 Dec;11(12):791-7. doi: 10.1038/nrn2935. Epub 2010 Nov 19. Review.

PMID:
21088684
[PubMed - indexed for MEDLINE]
6.

Possible involvement of the relationship of LRRK2 and autophagy in Parkinson's disease.

Bravo-San Pedro JM, Gómez-Sánchez R, Niso-Santano M, Pizarro-Estrella E, González-Polo RA, Fuentes JM.

Biochem Soc Trans. 2012 Oct;40(5):1129-33. Review.

PMID:
22988877
[PubMed - indexed for MEDLINE]
7.

Dysfunction of the autophagy/lysosomal degradation pathway is a shared feature of the genetic synucleinopathies.

Manzoni C, Lewis PA.

FASEB J. 2013 Sep;27(9):3424-9. doi: 10.1096/fj.12-223842. Epub 2013 May 16. Review.

PMID:
23682122
[PubMed - indexed for MEDLINE]
Free Article
8.

LRRK2 and autophagy: a common pathway for disease.

Manzoni C.

Biochem Soc Trans. 2012 Oct;40(5):1147-51. Review.

PMID:
22988880
[PubMed - indexed for MEDLINE]
9.

Molecular biology changes associated with LRRK2 mutations in Parkinson's disease.

Lu YW, Tan EK.

J Neurosci Res. 2008 Jul;86(9):1895-901. doi: 10.1002/jnr.21656. Review.

PMID:
18338801
[PubMed - indexed for MEDLINE]
10.

Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.

Greggio E.

Biochem Soc Trans. 2012 Oct;40(5):1058-62. Review.

PMID:
22988865
[PubMed - indexed for MEDLINE]
11.

Leucine-rich repeat kinase 2 (LRRK2) cellular biology: a review of recent advances in identifying physiological substrates and cellular functions.

Drolet RE, Sanders JM, Kern JT.

J Neurogenet. 2011 Dec;25(4):140-51. doi: 10.3109/01677063.2011.627072. Epub 2011 Nov 11. Review.

PMID:
22077787
[PubMed - indexed for MEDLINE]
12.

Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications.

Yue Z, Lachenmayer ML.

Mov Disord. 2011 Jul;26(8):1386-97. doi: 10.1002/mds.23737. Epub 2011 Apr 29. Review.

PMID:
21538530
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.

Greggio E, Cookson MR.

ASN Neuro. 2009 Apr 14;1(1). pii: e00002. doi: 10.1042/AN20090007. Review.

PMID:
19570025
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

The biology and pathobiology of LRRK2: implications for Parkinson's disease.

Moore DJ.

Parkinsonism Relat Disord. 2008;14 Suppl 2:S92-8. doi: 10.1016/j.parkreldis.2008.04.010. Epub 2008 Jul 7. Review.

PMID:
18602856
[PubMed - indexed for MEDLINE]
15.

On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies.

Daniëls V, Baekelandt V, Taymans JM.

Neurosignals. 2011;19(1):1-15. doi: 10.1159/000324488. Epub 2011 Mar 23. Review.

PMID:
21430363
[PubMed - indexed for MEDLINE]
16.

Cellular effects of LRRK2 mutations.

Cookson MR.

Biochem Soc Trans. 2012 Oct;40(5):1070-3. Review.

PMID:
22988867
[PubMed - indexed for MEDLINE]
17.

Role of LRRK2 kinase dysfunction in Parkinson disease.

Kumar A, Cookson MR.

Expert Rev Mol Med. 2011 Jun 13;13:e20. doi: 10.1017/S146239941100192X. Review.

PMID:
21676337
[PubMed - indexed for MEDLINE]
18.

Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.

Ray S, Liu M.

Future Med Chem. 2012 Sep;4(13):1701-13. doi: 10.4155/fmc.12.110. Review.

PMID:
22924508
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Insights into LRRK2 function and dysfunction from transgenic and knockout rodent models.

Sloan M, Alegre-Abarrategui J, Wade-Martins R.

Biochem Soc Trans. 2012 Oct;40(5):1080-5. Review.

PMID:
22988869
[PubMed - indexed for MEDLINE]
20.

LRRK2 signaling pathways: the key to unlocking neurodegeneration?

Berwick DC, Harvey K.

Trends Cell Biol. 2011 May;21(5):257-65. doi: 10.1016/j.tcb.2011.01.001. Epub 2011 Feb 8. Review.

PMID:
21306901
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk